Core Insights - Daxor Corporation will exhibit at the AAHFN 20th Annual Meeting from June 20-22, 2024, showcasing its blood volume measurement technology [1][4] - The AAHFN is focused on improving heart failure patient outcomes through education, clinical practice, and research [1] - Daxor's BVA technology is positioned as a transformative tool in heart failure management, aiming to reduce hospital stays, 30-day readmissions, and mortality rates [4] Company Overview - Daxor Corporation is a leader in blood volume measurement technology, known for its BVA-100® diagnostic test, which is FDA-cleared for accurate blood volume quantification [8] - Over 65,000 tests have been conducted in U.S. hospitals, contributing to improved performance metrics in various medical conditions, particularly in heart failure and critical care [8] - The company is engaged in ongoing trials for heart failure treatment with NIH support and is developing analyzers for combat casualty care in collaboration with the U.S. Department of Defense [8]
Daxor Corporation to Showcase the Benefits of BVA-100™ Guided-Care at the American Association of Heart Failure Nurses (AAHFN) 20th Annual Meeting